Sigilon Therapeutics is based in Cambridge, Massachusetts. It has raised $363M in total funding. Latest round: Growth.
Sigilon Therapeutics funding overview
Sigilon Therapeutics is based in Cambridge, Massachusetts. Sigilon Therapeutics has raised $363M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Growth announced in August 2023. The round record for Sigilon Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Eli Lilly and Company, BlackRock, Flagship Pioneering, Longevity Fund, Canada Pension Plan Investment Board. 5 distinct backers are named across the disclosed rounds.
Sigilon Therapeutics at a glance
Total raised
$363M
Latest round
Growth
Latest round date
August 2023
Headquarters
Cambridge, Massachusetts
Notable investors
Eli Lilly and Company, BlackRock, Flagship Pioneering, Longevity Fund, Canada Pension Plan Investment Board
Frequently asked about Sigilon Therapeutics funding
How much has Sigilon Therapeutics raised?
Sigilon Therapeutics has raised $363M in total disclosed funding across the rounds on record.
Who has invested in Sigilon Therapeutics?
Eli Lilly and Company, BlackRock, Flagship Pioneering, Longevity Fund, Canada Pension Plan Investment Board are named among the investors backing Sigilon Therapeutics.
What was the latest Sigilon Therapeutics funding round?
The most recent disclosed round is a Growth, announced in August 2023.
Where is Sigilon Therapeutics based?
Sigilon Therapeutics is based in Cambridge, Massachusetts.
When did Sigilon Therapeutics last raise?
The last disclosed Sigilon Therapeutics round closed in August 2023 at Growth.
Round data for Sigilon Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Cambridge and backer lists below.
